Donate
(Vail Daily) Psilocybin, the active psychedelic ingredient in magic mushrooms, has been proven to impact patients with depression positively. Vail Health’s OPTIMIZE study, which will administer doses of psilocybin to all 140 participants, aims to investigate how to predict and enhance this effect.
(Psychedelic Alpha) Dr. Charles Raison has long held an interest in melding ancient practices with today’s mental health system, looking at how things like meditation and psychedelics might interface with modern psychiatry.
(Vail Daily) In April, Vail Health’s Behavioral Health Innovation Center will kick off the second of two studies aimed at targeting depression. The OPTIMIZE study will examine the impacts of psilocybin, the active ingredient in psychedelic mushrooms, on people with major depressive disorder.
(CNN) For a good number of people antidepressants have been a blessing, at least at the beginning of treatment, but for up to a third of depressed patients, antidepressants fail to work at all, said Dr. Charles Raison.
(Newsweek) Millions of Americans struggling with depression could benefit from the active ingredient in magic mushrooms, new research suggests. However, approval of such treatments will depend on the U.S. Food and Drug Administration (FDA).